Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on January 6, 2017. The filing discloses a proposed merger between OncoGenex and Achieve Life Sciences, Inc. ("Achieve"). The report includes an investor presentation from Achieve intended for the J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for either company. This document serves as a notification of the proposed transaction and the availability of an investor presentation rather than a financial results report.
Material Changes
The primary material event is the proposed merger between OncoGenex and Achieve. OncoGenex intends to file a registration statement on Form S-4 with the SEC, which will contain a joint proxy statement/prospectus detailing the transaction.
Guidance, Outlook, and Risks
- Outlook: The companies plan to present an investor presentation at the J.P. Morgan Healthcare Conference regarding the merger.
- Process: A joint proxy statement/prospectus will be sent to stockholders of both companies for review and voting.
- Legal Disclaimer: This communication does not constitute an offer to sell or a solicitation of an offer to buy securities. No offering will be made except via a prospectus meeting Section 10 requirements of the Securities Act of 1933.
- Participants: Executive officers and directors of both OncoGenex and Achieve may be deemed participants in the solicitation of proxies.
Investor Verification Checklist
- Verify the terms of the proposed merger in the upcoming Form S-4 and joint proxy statement/prospectus.
- Review the Achieve Life Sciences, Inc. investor presentation attached as Exhibit 99.1.
- Confirm the filing status of the Form S-4 registration statement with the SEC.
- Check for any amendments or supplements to the proxy materials before making voting decisions.